Antidepressants Drugs Market by Disease Type and Geography - Forecast and Analysis 2022-2026

The antidepressants drugs market share is expected to increase to USD 5.22 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%.

This antidepressants drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers antidepressants drugs market segmentations by disease type (major compulsive disorder, obsessive compulsive disorder, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The antidepressants drugs market report also offers information on several market vendors, including AbbVie Inc., Alkermes Public Ltd. Co., Bausch Health Companies Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Luye Pharma Group Ltd., MagVenture AS, Otsuka Holdings Co. Ltd., Pfizer Inc., SK Biopharmaceuticals Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.

What will the Antidepressants Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Antidepressants Drugs Market Size for the Forecast Period and Other Important Statistics

 

Antidepressants Drugs Market: Key Drivers, Trends, and Challenges

The rising prevalence of depression is notably driving the antidepressants drugs market growth, although factors such as social stigma associated with depression and lack of awareness among people may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the antidepressants drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Antidepressants Drugs Market Driver

• The rising prevalence of depression is one of the key drivers fueling the antidepressants drugs market growth.
• Depression affects men, women, and children. It is most evident in the childhood, adolescence, or early adulthood stages.
• Depression cases have increased significantly since 2021 owing to the negative impact of the pandemic on mental health.
• The most significant predictors of depressive symptoms during the pandemic were low household income, the experience of multiple pandemic-related stressors, and negative impact on health.
• As per the Lancet study, 76 million additional cases of anxiety disorders and 53 million of MDD were recorded in 2020, due to the COVID-19 pandemic. This represents a 26% and 28% increase in the two disorders, respectively. Such increasing cases of anxiety disorder will drive market growth during the forecast period.

Key Antidepressants Drugs Market Trend

The development and approval of new drugs is one of the key antidepressants drugs market trends propelling the market growth. The increasing incidences of depression have led pharmaceutical vendors to develop the following new antidepressant drugs for approval:

• In February 2022, AbbVie announced that it had submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the US FDA for the adjunctive treatment of MDD in patients receiving antidepressant therapy at present. The submission is supported by results from previously announced clinical trials.
• In June 2021, Alkermes plc announced that the US Food and Drug Administration (FDA) approved LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia (depressive episode) and for the treatment of adults with bipolar I disorder (depressive episode).

The aforementioned instances of the development and approval of new drugs are anticipated to propel the market growth during the forecast period.

Key Antidepressants Drugs Market Challenge

• The social stigma associated with depression and lack of awareness among people is one of the factors hampering the antidepressants drugs market growth.
• Most people do not know what to do about depression even when they find it. People with mental health problems can also experience discrimination in all aspects of their lives.
• Ignorance of depression can lead to the premature loss of self-dependence, reduced participation in social interactions, and low self-confidence. Stigmas related to depression not only affect the well-being of a person by preventing them from seeking medical help but also affect the volume consumption of the drugs used for the treatment.
• Inaccurate assumptions may lead to wrong interpretations about the impact of the disease. Stigmas associated with these diseases can have an adverse impact on the social life of caregivers, including family members.

The above-mentioned stigmas will reduce the adoption of new drugs and thereby will challenge the market growth during the forecast period.

This antidepressants drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global antidepressants drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the antidepressants drugs market during the forecast period.

Who are the Major Antidepressants Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• Alkermes Public Ltd. Co.
• Bausch Health Companies Inc.
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• H Lundbeck AS
• Johnson and Johnson
• Lupin Ltd.
• Luye Pharma Group Ltd.
• MagVenture AS
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• SK Biopharmaceuticals Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

 

This statistical study of the antidepressants drugs market encompasses successful business strategies deployed by the key vendors. The antidepressants drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• Abbvie.com - The company offers novel, oral, rapid-acting antidepressant drugs such as AGN 241751.
• Alkermes.com - The company offers antidepressant drugs such as ALKS 5461 for the treatment of the major depressive disorder.
• Bauschhealth.com - The company offers antidepressants drugs such as Aplenzin for the treatment of major depressive disorder and seasonal affective disorder.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The antidepressants drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Antidepressants Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the antidepressants drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Antidepressants Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the antidepressants drugs market in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia.

Government initiatives to combat depression will facilitate the antidepressants drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

There was a rise in the depression in the region due to the outbreak of COVID-19. Thus, the increasing cases of depression since the pandemic will lead to the approval of new antidepressant drugs in the region. Thereby, it is anticipated that the market in focus will grow positively during the forecast period.

What are the Revenue-generating Disease Type Segments in the Antidepressants Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The antidepressants drugs market share growth by the major compulsive disorder segment will be significant during the forecast period. Major compulsive disorder is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, and others. In 2008, major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide by World Health Organization (WHO), which has projected that this disease will rank first by 2030. However, FDA-approved medications for the treatment of MDD. Such an increase in major depressive disorder will drive the market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the antidepressants drugs market size and actionable market insights on post COVID-19 impact on each segment.

Similar Reports:

• Antidepressant Market in the US 2015-2019

 

Antidepressants Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.44%
Market growth 2022-2026	$ 5.22 billion
Market structure	Fragmented
YoY growth (%)	4.29
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, Greece, China, and India
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., Alkermes Public Ltd. Co., Bausch Health Companies Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Luye Pharma Group Ltd., MagVenture AS, Otsuka Holdings Co. Ltd., Pfizer Inc., SK Biopharmaceuticals Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Antidepressants Drugs Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive antidepressants drugs market growth during the next five years
• Precise estimation of the antidepressants drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the antidepressants drugs industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of antidepressants drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch